Cellectar Biosciences, Inc. (NASDAQ:CLRB) Shares Sold by Barclays PLC

Barclays PLC trimmed its position in Cellectar Biosciences, Inc. (NASDAQ:CLRB) by 30.0% during the third quarter, Holdings Channel.com reports. The firm owned 120,497 shares of the biopharmaceutical company’s stock after selling 51,700 shares during the period. Barclays PLC’s holdings in Cellectar Biosciences were worth $258,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the company. Geode Capital Management LLC grew its stake in shares of Cellectar Biosciences by 3.3% during the third quarter. Geode Capital Management LLC now owns 352,452 shares of the biopharmaceutical company’s stock worth $754,000 after purchasing an additional 11,266 shares in the last quarter. Oppenheimer & Co. Inc. purchased a new stake in Cellectar Biosciences during the 3rd quarter worth about $27,000. Sequoia Financial Advisors LLC acquired a new position in shares of Cellectar Biosciences during the 3rd quarter worth about $51,000. XTX Topco Ltd increased its holdings in shares of Cellectar Biosciences by 432.4% in the 2nd quarter. XTX Topco Ltd now owns 63,304 shares of the biopharmaceutical company’s stock valued at $158,000 after acquiring an additional 51,413 shares during the last quarter. Finally, Rosalind Advisors Inc. increased its holdings in shares of Cellectar Biosciences by 35.7% in the 3rd quarter. Rosalind Advisors Inc. now owns 3,671,550 shares of the biopharmaceutical company’s stock valued at $7,857,000 after acquiring an additional 965,934 shares during the last quarter. 16.41% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on CLRB. StockNews.com started coverage on Cellectar Biosciences in a report on Tuesday. They issued a “sell” rating for the company. LADENBURG THALM/SH SH initiated coverage on shares of Cellectar Biosciences in a research report on Thursday, December 5th. They set a “buy” rating and a $13.00 price objective for the company. Finally, Oppenheimer reaffirmed a “market perform” rating on shares of Cellectar Biosciences in a research report on Wednesday, December 11th.

Cellectar Biosciences Stock Up 0.5 %

Shares of NASDAQ CLRB opened at $0.24 on Tuesday. The business has a 50-day moving average price of $0.88 and a 200 day moving average price of $1.71. The stock has a market cap of $10.05 million, a PE ratio of -0.14 and a beta of 1.04. Cellectar Biosciences, Inc. has a 52-week low of $0.22 and a 52-week high of $4.45.

Cellectar Biosciences (NASDAQ:CLRB) last issued its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter. Sell-side analysts anticipate that Cellectar Biosciences, Inc. will post -1.59 earnings per share for the current year.

Cellectar Biosciences Profile

Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.